Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure

Exclusion Criteria

• •History of acquired iron overload; known haemochromatosis or first relatives with haemochromatosis; and allergic disorders (asthma, eczema, and anaphylactic reactions).
• •Known hypersensitivity to parental iron preparations.
• •Known active infection, bleeding, malignancy and haemolytic anaemia.
• •History of chronic liver disease and/or alanine transaminase (ALT) or aspartate transaminase (AST) \>3 times the upper limit of the normal range; chronic lung disease; myelodysplastic disorder; and known HIV/AIDS disease.
• •Recipient of immunosuppressive therapy or renal dialysis.
• •History of erythropoietin, IV or oral iron therapy, and blood transfusion in previous 30 days.
• •Unstable angina pectoris, as judged by the investigator; severe uncorrected valvular disease or left ventricular outflow obstruction; obstructive cardiomyopathy; uncontrolled fast atrial fibrillation or flutter (heart rate \>110 beats per minute \[bpm\]); uncontrolled symptomatic brady- or tachyarrhythmias.
• •Musculoskeletal limitation that, in the judgement of the investigator, would impair cardiopulmonary exercise testing.
• •Pregnant or breast-feeding
• •Inability to comprehend study protocol
• •Parallel participation in another clinical trial